Tillman Gerngross (Adagio)
August 2, 2021 08:58 AM EDTUpdated 10:24 AM
Bioregnum

A glob­al pan­dem­ic fi­as­co sets the stage for Till­man Gern­gross to in­tro­duce his biotech uni­corn to Wall Street

This morn­ing we got a bet­ter look at the num­bers Till­man Gern­gross has in mind for his pan­dem­ic play at Ada­gio Ther­a­peu­tics. And not sur­pris­ing­ly …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

AI biotech In­sil­i­co Med­i­cine goes for third at­tempt at Hong Kong IPO

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times